Success Metrics

Clinical Success Rate
100.0%

Based on 9 completed trials

Completion Rate
100%(9/9)
Active Trials
0(0%)
Results Posted
100%(9 trials)

Phase Distribution

Ph phase_1
7
78%
Ph phase_2
1
11%
Ph phase_3
1
11%

Phase Distribution

7

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
7(77.8%)
Phase 2Efficacy & side effects
1(11.1%)
Phase 3Large-scale testing
1(11.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

9 of 9 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

9

all time

Status Distribution
Completed(9)

Detailed Status

Completed9

Development Timeline

Analytics

Development Status

Total Trials
9
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 17 (77.8%)
Phase 21 (11.1%)
Phase 31 (11.1%)

Trials by Status

completed9100%

Recent Activity

0 active trials
Showing 5 of 9
completedphase_1

A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer

NCT00585195
completedphase_1

MEK and MET Inhibition in Colorectal Cancer

NCT02510001
completedphase_2

An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

NCT00932451
completedphase_3

An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

NCT00932893
completedphase_1

A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer

NCT01121575
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT00585195Phase 1

A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer

Completed
NCT02510001Phase 1

MEK and MET Inhibition in Colorectal Cancer

Completed
NCT00932451Phase 2

An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

Completed
NCT00932893Phase 3

An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

Completed
NCT01121575Phase 1

A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer

Completed
NCT00965731Phase 1

Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer

Completed
NCT01082380Phase 1

Radiolabeled [14C]PF-02341066 Study To Investigate The Absorption, Metabolism And Excretion In Healthy Male Volunteers

Completed
NCT01250730Phase 1

A Study In Japanese Healthy Male Volunteers To Investigate The Safety, Tolerability And Pharmacokinetics Of PF-02341066

Completed
NCT00939731Phase 1

Relative Drug Exposures Of Two Formulations of PF-02341066

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9